Recent Updates
Recently added Catalysts
OVID Positive Sentiment

NORD

Friday, September 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: NORD is a 501(c)(3) patient advocacy organization focused on rare diseases. With over 280 member organizations, it aims to identify, treat, and cure rare disorders through education, advocacy, research, and patient services. The organization is dedicated to supporting individuals affected by these conditions.
Price reaction · baseline $3.57 (2023-09-22T16:35:00.000Z) · hit during market hours · 17 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+2%

Market Sentiment Analysis

POSITIVE FACTORS

  • NORD is dedicated to supporting individuals with rare diseases.
  • The organization has over 280 patient organization members.
  • NORD focuses on education, advocacy, and research for rare disorders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

NORD, a 501(c)(3) organization, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 280 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.
Visit Site »

Frequently Asked Questions

What does NORD stand for?

NORD stands for the National Organization for Rare Disorders.

How many member organizations does NORD have?

NORD has more than 280 member patient organizations.

What is NORD's mission?

NORD is dedicated to the identification, treatment, and cure of rare disorders.

What programs does NORD offer?

NORD offers education, advocacy, research, and patient services.

ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare NORD rare diseases patient advocacy treatment research
Last updated: Sep 22, 2023

Biotech snapshot

Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk

Catalyst track record

+622%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →